{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:29:00Z","timestamp":1794508140362,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["No.22075247"],"award-info":[{"award-number":["No.22075247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang provincial Natural Foundation of China","award":["No.LGF21C100001"],"award-info":[{"award-number":["No.LGF21C100001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is reported that pulmonary fibrosis has become one of the major long-term complications of COVID-19, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. Recently, inhalable nanocarriers have received more attention due to their ability to improve the solubility of insoluble drugs, penetrate biological barriers of the lungs and target fibrotic tissues in the lungs. The inhalation route has many advantages as a non-invasive method of administration and the local delivery of anti-fibrosis agents to fibrotic tissues like direct to the lesion from the respiratory system, high delivery efficiency, low systemic toxicity, low therapeutic dose and more stable dosage forms. In addition, the lung has low biometabolic enzyme activity and no hepatic first-pass effect, so the drug is rapidly absorbed after pulmonary administration, which can significantly improve the bioavailability of the drug. This paper summary the pathogenesis and current treatment of pulmonary fibrosis and reviews various inhalable systems for drug delivery in the treatment of pulmonary fibrosis, including lipid-based nanocarriers, nanovesicles, polymeric nanocarriers, protein nanocarriers, nanosuspensions, nanoparticles, gold nanoparticles and hydrogel, which provides a theoretical basis for finding new strategies for the treatment of pulmonary fibrosis and clinical rational drug use.<\/jats:p>","DOI":"10.1186\/s12951-023-01971-7","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T04:01:42Z","timestamp":1688788902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects"],"prefix":"10.1186","volume":"21","author":[{"given":"Qianyu","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanrong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"1971_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1084\/jem.20110551","volume":"208","author":"TA Wynn","year":"2011","unstructured":"Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208:1339\u201350.","journal-title":"J Exp Med"},{"key":"1971_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811\u201323.","journal-title":"N Engl J Med"},{"key":"1971_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/ijms20030593","volume":"20","author":"B Ballester","year":"2019","unstructured":"Ballester B, Milara J, Cortijo J. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci. 2019;20:593.","journal-title":"Int J Mol Sci"},{"key":"1971_CR4","doi-asserted-by":"publisher","first-page":"105802","DOI":"10.1016\/j.biocel.2020.105802","volume":"126","author":"Z Deng","year":"2020","unstructured":"Deng Z, Fear MW, Choi YS, Wood FM, Allahham A, Mutsaers SE, Pr\u00eale CM. The extracellular matrix and mechanotransduction in pulmonary fibrosis. Int J Biochem Cell B. 2020;126:105802.","journal-title":"Int J Biochem Cell B"},{"key":"1971_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:1\u201319.","journal-title":"Nat Rev Dis Primers"},{"key":"1971_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s40572-018-0219-7","volume":"5","author":"N Assad","year":"2018","unstructured":"Assad N, Sood A, Campen MJ, Zychowski KE. Metal-induced pulmonary fibrosis. Curr Environ Health Rep. 2018;5:486\u201398.","journal-title":"Curr Environ Health Rep"},{"key":"1971_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-017-0698-3","volume":"19","author":"G Sgalla","year":"2018","unstructured":"Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respirs Res. 2018;19:1\u201318.","journal-title":"Respirs Res"},{"key":"1971_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1515\/cclm-2021-1021","volume":"60","author":"A Vianello","year":"2022","unstructured":"Vianello A, Guarnieri G, Braccioni F, Lococo S, Molena B, Cecchetto A, Giraudo C, De Marchi LB, Caminati M, Senna G. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med. 2022;60:307\u201316.","journal-title":"Clin Chem Lab Med"},{"key":"1971_CR9","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/jmv.26634","volume":"93","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wu Z, Li JW, Tan K, Yang W, Zhao H, Wang GQ. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19. J Med Virol. 2021;93:1378\u201386.","journal-title":"J Med Virol"},{"issue":"7","key":"1971_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/jan.15187","volume":"78","author":"N Ryan","year":"2022","unstructured":"Ryan N, Meskell P. The experience of people with idiopathic pulmonary fibrosis living through the COVID-19 pandemic. J Adv Nurs. 2022;78(7):2232\u201344.","journal-title":"J Adv Nurs"},{"key":"1971_CR11","doi-asserted-by":"publisher","first-page":"300607","DOI":"10.1016\/j.hpr.2022.300607","volume":"27","author":"LV Carvalho","year":"2022","unstructured":"Carvalho LV, da Silva SC, Fontes JL, Cardoso L, Salomar M, Duarte-Neto AN, Figueira C, Brito R, Mesquita B, de Freitas LA. COVID-19 beyond DAD: persisting microcirculation thrombosis, hidden infections, and early pulmonary fibrosis as remaining challenges of the disease. Hum Pathol Rep. 2022;27:300607.","journal-title":"Hum Pathol Rep"},{"key":"1971_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/1060028014551015","volume":"48","author":"JR Covvey","year":"2014","unstructured":"Covvey JR, Mancl EE. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis. Ann Pharmacother. 2014;48:1611\u20139.","journal-title":"Ann Pharmacother"},{"key":"1971_CR13","doi-asserted-by":"publisher","first-page":"607689","DOI":"10.3389\/fphar.2020.607689","volume":"11","author":"M Skibba","year":"2020","unstructured":"Skibba M, Drelich A, Poellmann M, Hong S, Brasier AR. Nanoapproaches to modifying epigenetics of epithelial mesenchymal transition for treatment of pulmonary fibrosis. Front Pharmacol. 2020;11:607689.","journal-title":"Front Pharmacol"},{"key":"1971_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","volume":"56","author":"S Homma","year":"2018","unstructured":"Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268\u201391.","journal-title":"Respir Investig"},{"key":"1971_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"M Kato","year":"2019","unstructured":"Kato M, Sasaki S, Nakamura T, Kurokawa K, Yamada T, Ochi Y, Ihara H, Takahashi F, Takahashi K. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep-UK. 2019;9:1\u20139.","journal-title":"Sci Rep-UK"},{"key":"1971_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s12325-019-00928-3","volume":"36","author":"I Hanta","year":"2019","unstructured":"Hanta I, Cilli A, Sevinc C. The effectiveness, safety, and tolerability of Pirfenidone in idiopathic pulmonary fibrosis: a retrospective study. Adv Ther. 2019;36:1126\u201331.","journal-title":"Adv Ther"},{"key":"1971_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2021.03.017","volume":"164","author":"M Ghumman","year":"2021","unstructured":"Ghumman M, Dhamecha D, Gonsalves A, Fortier L, Sorkhdini P, Zhou Y, Menon JU. Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment. Eur J Pharm Biopharm. 2021;164:1\u201312.","journal-title":"Eur J Pharm Biopharm"},{"key":"1971_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/resp.13024","volume":"22","author":"JA Galli","year":"2017","unstructured":"Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22:1171\u20138.","journal-title":"Respirology"},{"key":"1971_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40820-020-00482-6","volume":"12","author":"W Mu","year":"2020","unstructured":"Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Lett. 2020;12:1\u201324.","journal-title":"Nano-Micro Lett"},{"key":"1971_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.15212\/bioi-2021-0028","volume":"13","author":"R Thubelihle Ndebele","year":"2022","unstructured":"Thubelihle Ndebele R, Yao Q, Shi Y-N, Zhai Y-Y, Xu H-L, Lu C-T, Zhao Y-Z. Progress in the application of nano-and micro-based drug delivery systems in pulmonary drug delivery. BIO Integr. 2022;13:71\u201383.","journal-title":"BIO Integr"},{"key":"1971_CR21","doi-asserted-by":"publisher","first-page":"1606628","DOI":"10.1002\/adma.201606628","volume":"29","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, et al. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. Adv Mater. 2017;29:1606628.","journal-title":"Adv Mater"},{"key":"1971_CR22","doi-asserted-by":"publisher","first-page":"eabn7162","DOI":"10.1126\/sciadv.abn7162","volume":"8","author":"X Bai","year":"2022","unstructured":"Bai X, Zhao G, Chen Q, Li Z, Gao M, Ho W, Xu X, Zhang XQ. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv. 2022;8:eabn7162.","journal-title":"Sci Adv"},{"key":"1971_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fphar.2013.00173","volume":"4","author":"A Camelo","year":"2014","unstructured":"Camelo A, Dunmore R, Sleeman MA, Clarke DL. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol. 2014;4:173.","journal-title":"Front Pharmacol"},{"key":"1971_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/thoraxjnl-2017-210070","volume":"73","author":"JM Wang","year":"2018","unstructured":"Wang JM, Robertson SH, Wang Z, He M, Virgincar RS, Schrank GM, Smigla RM, O\u2019Riordan TG, Sundy J, Ebner L. Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. Thorax. 2018;73:21\u20138.","journal-title":"Thorax"},{"key":"1971_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.tim.2019.07.004","volume":"27","author":"S Fulaz","year":"2019","unstructured":"Fulaz S, Vitale S, Quinn L, Casey E. Nanoparticle\u2013biofilm interactions: the role of the EPS matrix. Trends Microbiol. 2019;27:915\u201326.","journal-title":"Trends Microbiol"},{"key":"1971_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jconrel.2022.05.006","volume":"347","author":"Q Liu","year":"2022","unstructured":"Liu Q, Zhang X, Xue J, Chai J, Qin L, Guan J, Zhang X, Mao S. Exploring the intrinsic micro\u2212\/nanoparticle size on their in vivo fate after lung delivery. J Controll Release. 2022;347:435\u201348.","journal-title":"J Controll Release"},{"key":"1971_CR27","doi-asserted-by":"publisher","first-page":"119671","DOI":"10.1016\/j.ijpharm.2020.119671","volume":"587","author":"T Praphawatvet","year":"2020","unstructured":"Praphawatvet T, Peters JI, Williams RO III. Inhaled nanoparticles\u2014an updated review. Int J Pharmaceut. 2020;587:119671.","journal-title":"Int J Pharmaceut"},{"key":"1971_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejpb.2022.01.009","volume":"172","author":"J Zhao","year":"2022","unstructured":"Zhao J, Qin L, Song R, Su J, Yuan Y, Zhang X, Mao S. Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung. Eur J Pharm Biopharma. 2022;172:101\u201311.","journal-title":"Eur J Pharm Biopharma"},{"key":"1971_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0142-9612(02)00445-3","volume":"24","author":"D Fischer","year":"2003","unstructured":"Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24:1121\u201331.","journal-title":"Biomaterials"},{"key":"1971_CR30","doi-asserted-by":"crossref","unstructured":"Murali S, Mangotra A. NanoToxicity\u2014a bird's eye view of toxicological aspects. 2018.","DOI":"10.31031\/RDMS.2018.07.000655"},{"key":"1971_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/2665980801999201230095324","volume":"1","author":"S Asati","year":"2021","unstructured":"Asati S, Sahu A, Jain A. Nanotoxicity: the dark side of nanoformulations. Curr Nanotoxicity Prev. 2021;1:6\u201325.","journal-title":"Curr Nanotoxicity Prev"},{"key":"1971_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10837450.2012.757782","volume":"19","author":"Y Wei","year":"2014","unstructured":"Wei Y, Zhao L. Passive lung-targeted drug delivery systems via intravenous administration. Pharm Dev Technol. 2014;19:129\u201336.","journal-title":"Pharm Dev Technol"},{"key":"1971_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.arbres.2019.05.008","volume":"55","author":"M Molina-Molina","year":"2019","unstructured":"Molina-Molina M. The future of pharmacological treatment in idiopathic pulmonary fibrosis. Arch Bronconeumol. 2019;55:642\u20137.","journal-title":"Arch Bronconeumol"},{"key":"1971_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S2213-2600(18)30502-2","volume":"7","author":"PM George","year":"2019","unstructured":"George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Resp Med. 2019;7:271\u201382.","journal-title":"Lancet Resp Med"},{"key":"1971_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","volume":"219","author":"A Kuzmov","year":"2015","unstructured":"Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Controll Release. 2015;219:500\u201318.","journal-title":"J Controll Release"},{"key":"1971_CR36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3906\/sag-1912-209","volume":"50","author":"R Ak\u00e7an","year":"2020","unstructured":"Ak\u00e7an R, Aydogan HC, Yildirim M\u015e, Ta\u015ftekin B, Sa\u011flam N. Nanotoxicity: a challenge for future medicine. Turk J Med Sci. 2020;50:1180\u201396.","journal-title":"Turk J Med Sci"},{"key":"1971_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2017.03.392","volume":"254","author":"M Gaber","year":"2017","unstructured":"Gaber M, Medhat W, Hany M, Saher N, Fang J-Y, Elzoghby A. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: challenges and outcomes. J Controll Release. 2017;254:75\u201391.","journal-title":"J Controll Release"},{"key":"1971_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajps.2015.11.034","volume":"11","author":"S Unida","year":"2016","unstructured":"Unida S, Ito Y, Onodera R, Tahara K, Takeuchi H. Inhalation properties of water-soluble drug loaded liposomes atomized by nebulizer. Asian J Pharm Sci. 2016;11:205\u20136.","journal-title":"Asian J Pharm Sci"},{"key":"1971_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000445116","volume":"25","author":"M Rudokas","year":"2016","unstructured":"Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Prin Pract. 2016;25:60\u201372.","journal-title":"Med Prin Pract"},{"key":"1971_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejpb.2012.11.023","volume":"84","author":"V Ivanova","year":"2013","unstructured":"Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm. 2013;84:335\u201344.","journal-title":"Eur J Pharm Biopharm"},{"key":"1971_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","volume":"15","author":"T Lammers","year":"2020","unstructured":"Lammers T, Sofias AM, Van der Meel R, Schiffelers R, Storm G, Tacke F, Koschmieder S, Br\u00fcmmendorf TH, Kiessling F, Metselaar JM. Dexamethasone nanomedicines for COVID-19. Nat Nanotechnol. 2020;15:622\u20134.","journal-title":"Nat Nanotechnol"},{"key":"1971_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/pr10061131","volume":"10","author":"P Murthy","year":"2022","unstructured":"Murthy P, Shaibie NA, Lim CL, Ling APK, Chye SM, Koh RY. An overview of herbal medicines for idiopathic pulmonary fibrosis. Processes. 2022;10:1131.","journal-title":"Processes"},{"key":"1971_CR43","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s13346-020-00857-7","volume":"11","author":"L Jiang","year":"2021","unstructured":"Jiang L, Li Y, Yu J, Wang J, Ju J, Dai J. A dry powder inhalable formulation of salvianolic acids for the treatment of pulmonary fibrosis: safety, lung deposition, and pharmacokinetic study. Drug Deliv Transl Res. 2021;11:1958\u201368.","journal-title":"Drug Deliv Transl Res"},{"key":"1971_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ajps.2017.08.005","volume":"13","author":"S Chennakesavulu","year":"2018","unstructured":"Chennakesavulu S, Mishra A, Sudheer A, Sowmya C, Reddy CS, Bhargav E. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis. Asian J Pharm Sci. 2018;13:91\u2013100.","journal-title":"Asian J Pharm Sci"},{"issue":"11","key":"1971_CR45","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/pharmaceutics13111851","volume":"13","author":"S Kotta","year":"2021","unstructured":"Kotta S, Aldawsari HM, Badr-Eldin SM, Binmahfouz LS, Bakhaidar RB, Sreeharsha N, Nair AB, Ramnarayanan C. Aerosol delivery of surfactant liposomes for management of pulmonary fibrosis: an approach supporting pulmonary mechanics. Pharmaceutics. 2021;13(11):1851.","journal-title":"Pharmaceutics"},{"key":"1971_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4238\/gmr.15027309","volume":"15","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Zhu W, Cai X, Chen M. Atomized paclitaxel liposome inhalation treatment of bleomycin-induced pulmonary fibrosis in rats. Genet Mol Res. 2016;15:1\u201311.","journal-title":"Genet Mol Res"},{"issue":"18","key":"1971_CR47","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.3390\/molecules24183291","volume":"24","author":"L Pandolfi","year":"2019","unstructured":"Pandolfi L, Frangipane V, Bocca C, Marengo A, Tarro Genta E, Bozzini S, Morosini M, D\u2019Amato M, Vitulo S, Monti M. Hyaluronic acid-decorated liposomes as innovative targeted delivery system for lung fibrotic cells. Molecules. 2019;24(18):3291.","journal-title":"Molecules"},{"key":"1971_CR48","doi-asserted-by":"publisher","first-page":"eabb6075","DOI":"10.1126\/sciadv.abb6075","volume":"7","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang L, Wu G-R, Zhou Q, Yue H, Rao L-Z, Yuan T, Mo B, Wang F-X, Chen L-M. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci Adv. 2021;7:eabb6075.","journal-title":"Sci Adv"},{"key":"1971_CR49","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop K, Hoogenboom R, Fischer D, Schubert US. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed. 2010;49:6288\u2013308.","journal-title":"Angew Chem Int Ed"},{"key":"1971_CR50","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/03639045.2020.1825473","volume":"46","author":"K Togami","year":"2020","unstructured":"Togami K, Maruta Y, Nanbu M, Tada H, Chono S. Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with bleomycin-induced pulmonary fibrosis. Drug Dev Ind Pharm. 2020;46:1873\u201380.","journal-title":"Drug Dev Ind Pharm"},{"key":"1971_CR51","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","volume":"103","author":"A Khosa","year":"2018","unstructured":"Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598\u2013613.","journal-title":"Biomed Pharmacother"},{"key":"1971_CR52","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.nano.2017.04.005","volume":"13","author":"OB Garbuzenko","year":"2017","unstructured":"Garbuzenko OB, Ivanova V, Kholodovych V, Reimer DC, Reuhl KR, Yurkow E, Adler D, Minko T. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA (s). Nanomed-Nanotechnol. 2017;13:1983\u201392.","journal-title":"Nanomed-Nanotechnol"},{"key":"1971_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jconrel.2021.02.022","volume":"332","author":"H Keum","year":"2021","unstructured":"Keum H, Kim J, Yoo D, Kim TW, Seo C, Kim D, Jon S. Biomimetic lipid nanocomplexes incorporating STAT3-inhibiting peptides effectively infiltrate the lung barrier and ameliorate pulmonary fibrosis. J Controll Release. 2021;332:160\u201370.","journal-title":"J Controll Release"},{"key":"1971_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","volume":"86","author":"S Weber","year":"2014","unstructured":"Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86:7\u201322.","journal-title":"Eur J Pharm Biopharm"},{"key":"1971_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejpb.2016.07.018","volume":"108","author":"J Pardeike","year":"2016","unstructured":"Pardeike J, Weber S, Zarfl HP, Pagitz M, Zimmer A. Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons. Eur J Pharm Biopharm. 2016;108:269\u201376.","journal-title":"Eur J Pharm Biopharm"},{"key":"1971_CR56","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","volume":"415","author":"R Tiwari","year":"2011","unstructured":"Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharmaceut. 2011;415:232\u201343.","journal-title":"Int J Pharmaceut"},{"key":"1971_CR57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejpb.2014.07.007","volume":"88","author":"A Patil-Gadhe","year":"2014","unstructured":"Patil-Gadhe A, Kyadarkunte A, Patole M, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: Part II pulmonary drug delivery and in vitro\u2013in vivo aerosol performance. Eur J Pharm Biopharm. 2014;88:169\u201377.","journal-title":"Eur J Pharm Biopharm"},{"key":"1971_CR58","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.colsurfb.2014.12.041","volume":"126","author":"M Estanqueiro","year":"2015","unstructured":"Estanqueiro M, Amaral MH, Concei\u00e7\u00e3o J, Lobo JMS. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B. 2015;126:631\u201348.","journal-title":"Colloids Surf B"},{"key":"1971_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"P-UC Dinh","year":"2020","unstructured":"Dinh P-UC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, Huang K, Hensley MT, Harrell E, Vandergriff AC. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun. 2020;11:1\u201314.","journal-title":"Nat Commun"},{"key":"1971_CR60","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41565-021-00923-2","volume":"16","author":"Z Li","year":"2021","unstructured":"Li Z, Wang Z, Dinh P-UC, Zhu D, Popowski KD, Lutz H, Hu S, Lewis MG, Cook A, Andersen H. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat Nanotechnol. 2021;16:942\u201351.","journal-title":"Nat Nanotechnol"},{"key":"1971_CR61","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","volume":"269","author":"HM Abdelaziz","year":"2018","unstructured":"Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, Kabary DM, Freag MS, Samaha MW, Mortada SM. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Controll Release. 2018;269:374\u201392.","journal-title":"J Controll Release"},{"key":"1971_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02025-4","volume":"21","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Butnariu M, Rotariu LS, Sytar O, Sestito S, Rapposelli S, Akram M, Iqbal M, Krishna A. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell Int. 2021;21:1\u201321.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"1971_CR63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics9040053","volume":"9","author":"MA Mohammed","year":"2017","unstructured":"Mohammed MA, Syeda JT, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9(4):53.","journal-title":"Pharmaceutics"},{"key":"1971_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pestbp.2021.104919","volume":"178","author":"M Rashidipour","year":"2021","unstructured":"Rashidipour M, Rasoulian B, Maleki A, Davari B, Pajouhi N, Mohammadi E. Pectin\/chitosan\/tripolyphosphate encapsulation protects the rat lung from fibrosis and apoptosis induced by paraquat inhalation. Pestic Biochem Phys. 2021;178: 104919.","journal-title":"Pestic Biochem Phys"},{"key":"1971_CR65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijbiomac.2019.04.066","volume":"133","author":"G Zhang","year":"2019","unstructured":"Zhang G, Mo S, Fang B, Zeng R, Wang J, Tu M, Zhao J. Pulmonary delivery of therapeutic proteins based on zwitterionic chitosan-based nanocarriers for treatment on bleomycin-induced pulmonary fibrosis. Int J Biol Macromol. 2019;133:58\u201366.","journal-title":"Int J Biol Macromol"},{"key":"1971_CR66","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377\u201397.","journal-title":"Polymers"},{"key":"1971_CR67","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.biopha.2016.01.027","volume":"78","author":"C Lee","year":"2016","unstructured":"Lee C, Seo J, Hwang HS, Lee S, Lee ES, Lee EH, Choi H-G, Youn YS. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly (lactic-co-glycolic acid) nanoparticles. Biomed Pharmacother. 2016;78:226\u201333.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1971_CR68","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/ph14121225","volume":"14","author":"MH Elkomy","year":"2021","unstructured":"Elkomy MH, Khallaf RA, Mahmoud MO, Sayed RR, El-Kalaawy AM, Abdel-Razik A-RH, Aboud HM. Intratracheally inhalable nifedipine-loaded chitosan-PLGA nanocomposites as a promising nanoplatform for lung targeting: snowballed protection via regulation of TGF-\u03b2\/\u03b2-catenin pathway in bleomycin-induced pulmonary fibrosis. Pharmaceuticals. 2021;14(12):1225.","journal-title":"Pharmaceuticals"},{"key":"1971_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/DHPS.S224007","volume":"12","author":"S Gulati","year":"2020","unstructured":"Gulati S, Luckhardt TR. Updated evaluation of the safety, efficacy and tolerability of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Drug Healthc Patient. 2020;12:85\u201394.","journal-title":"Drug Healthc Patient"},{"key":"1971_CR70","doi-asserted-by":"publisher","first-page":"505101","DOI":"10.1088\/0957-4484\/23\/50\/505101","volume":"23","author":"R Trivedi","year":"2012","unstructured":"Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012;23:505101.","journal-title":"Nanotechnology"},{"key":"1971_CR71","unstructured":"Li F, Dai H, Geng J, Xu X. Inhibiting CXCR4\/CXCL12 axis attenuates lung fibrosis both in vitro and in vivo. Eur Respir Soc. 2012."},{"key":"1971_CR72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1165\/rcmb.2006-0187OC","volume":"37","author":"J Xu","year":"2007","unstructured":"Xu J, Mora A, Shim H, Stecenko A, Brigham KL, Rojas M. Role of the SDF-1\/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Resp Cell Mol. 2007;37:291\u20139.","journal-title":"Am J Resp Cell Mol"},{"issue":"11","key":"1971_CR73","doi-asserted-by":"publisher","first-page":"e79768","DOI":"10.1371\/journal.pone.0079768","volume":"8","author":"H-KG Shu","year":"2013","unstructured":"Shu H-KG, Yoon Y, Hong S, Xu K, Gao H, Hao C, Torres-Gonzalez E, Nayra C, Rojas M, Shim H. Inhibition of the CXCL12\/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis. PLoS ONE. 2013;8(11):e79768.","journal-title":"PLoS ONE"},{"key":"1971_CR74","first-page":"1765","volume":"14","author":"L Ding","year":"2018","unstructured":"Ding L, Zhu C, Yu F, Wu P, Chen G, Ullah A, Wang K, Sun M, Li J, Oupick\u00fd D. Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis. Nanomed-Nanotechnol. 2018;14:1765\u201376.","journal-title":"Nanomed-Nanotechnol"},{"key":"1971_CR75","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pupt.2016.01.001","volume":"36","author":"J Seo","year":"2016","unstructured":"Seo J, Lee C, Hwang HS, Kim B, Lee ES, Oh KT, Lim J-L, Choi H-G, Youn YS. Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. Pulm Pharmacol Ther. 2016;36:53\u201361.","journal-title":"Pulm Pharmacol Ther"},{"issue":"14","key":"1971_CR76","doi-asserted-by":"publisher","first-page":"e2107506","DOI":"10.1002\/adma.202107506","volume":"32","author":"R Zhang","year":"2022","unstructured":"Zhang R, Jing W, Chen C, Zhang S, Mohamed M, Sun P, Wang G, You W, Yang Z, Zhang J. Inhaled mRNA nanoformulation with biogenic ribosomal protein reverses established pulmonary fibrosis in a bleomycin-induced murine model. Adv Mater. 2022;32(14):e2107506.","journal-title":"Adv Mater"},{"key":"1971_CR77","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"1971_CR78","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1021\/acs.molpharmaceut.0c00026","volume":"17","author":"W Su","year":"2020","unstructured":"Su W, Liang Y, Meng Z, Chen X, Lu M, Han X, Deng X, Zhang Q, Zhu H, Fu T. Inhalation of tetrandrine-hydroxypropyl-\u03b2-cyclodextrin inclusion complexes for pulmonary fibrosis treatment. Mol Pharmaceut. 2020;17:1596\u2013607.","journal-title":"Mol Pharmaceut"},{"key":"1971_CR79","doi-asserted-by":"publisher","first-page":"110755","DOI":"10.1016\/j.colsurfb.2019.110755","volume":"188","author":"K Wang","year":"2020","unstructured":"Wang K, Lei Y, Xia D, Xu P, Zhu T, Jiang Z, Ma Y. Neutrophil membranes coated, antibiotic agent loaded nanoparticles targeting to the lung inflammation. Colloids Surf B. 2020;188:110755.","journal-title":"Colloids Surf B"},{"key":"1971_CR80","doi-asserted-by":"publisher","first-page":"L400","DOI":"10.1152\/ajplung.00041.2008","volume":"295","author":"JW Card","year":"2008","unstructured":"Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol-Lung C. 2008;295:L400\u201311.","journal-title":"Am J Physiol-Lung C"},{"key":"1971_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijpharm.2018.04.019","volume":"544","author":"V Vartiainen","year":"2018","unstructured":"Vartiainen V, Raula J, Bimbo LM, Viinam\u00e4ki J, Backman JT, Ugur N, Kauppinen E, Sutinen E, Joensuu E, Koli K. Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. Int J Pharmaceut. 2018;544:121\u20138.","journal-title":"Int J Pharmaceut"},{"key":"1971_CR82","first-page":"e106961","volume":"16","author":"AA Hemmati","year":"2021","unstructured":"Hemmati AA, Karampour NS, Dahanzadeh S, Sharif B, Makhmalzadeh AR, Ghafourian M. The protective effects of nebulized nano-curcumin against bleomycin-induced pulmonary fibrosis in rats. Jundishapur J Nat Pharma Prod. 2021;16:e106961.","journal-title":"Jundishapur J Nat Pharma Prod"},{"key":"1971_CR83","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.nano.2018.03.008","volume":"14","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Zhen M, Ma H, Li J, Shu C, Wang C. Inhalable gadofullerenol\/[70] fullerenol as high-efficiency ROS scavengers for pulmonary fibrosis therapy. Nanomed-Nanotechnol. 2018;14:1361\u20139.","journal-title":"Nanomed-Nanotechnol"},{"key":"1971_CR84","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules27051551","volume":"27","author":"W-C Ko","year":"2022","unstructured":"Ko W-C, Wang S-J, Hsiao C-Y, Hung C-T, Hsu Y-J, Chang D-C, Hung C-F. Pharmacological role of functionalized gold nanoparticles in disease applications. Molecules. 2022;27:1551.","journal-title":"Molecules"},{"key":"1971_CR85","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2019.08.015","volume":"310","author":"V Codullo","year":"2019","unstructured":"Codullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, Malatesta M, Calderan L, Cagnone M, Pacini C. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J Controll Release. 2019;310:198\u2013208.","journal-title":"J Controll Release"},{"key":"1971_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"L Pandolfi","year":"2020","unstructured":"Pandolfi L, Fusco R, Frangipane V, D\u2019Amico R, Giustra M, Bozzini S, Morosini M, D\u2019Amato M, Cova E, Ferrario G. Loading Imatinib inside targeted nanoparticles to prevent Bronchiolitis Obliterans Syndrome. Sci Rep-UK. 2020;10:1\u201310.","journal-title":"Sci Rep-UK"},{"key":"1971_CR87","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.biotechadv.2017.05.006","volume":"35","author":"S Naahidi","year":"2017","unstructured":"Naahidi S, Jafari M, Logan M, Wang Y, Yuan Y, Bae H, Dixon B, Chen P. Biocompatibility of hydrogel-based scaffolds for tissue engineering applications. Biotechnol Adv. 2017;35:530\u201344.","journal-title":"Biotechnol Adv"},{"key":"1971_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2016.71","volume":"1","author":"J Li","year":"2016","unstructured":"Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1:1\u201317.","journal-title":"Nat Rev Mater"},{"key":"1971_CR89","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nprot.2016.037","volume":"11","author":"D Loessner","year":"2016","unstructured":"Loessner D, Meinert C, Kaemmerer E, Martine LC, Yue K, Levett PA, Klein TJ, Melchels FP, Khademhosseini A, Hutmacher DW. Functionalization, preparation and use of cell-laden gelatin methacryloyl-based hydrogels as modular tissue culture platforms. Nat Protoc. 2016;11:727\u201346.","journal-title":"Nat Protoc"},{"key":"1971_CR90","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2019.02.017","volume":"203","author":"EA Shamskhou","year":"2019","unstructured":"Shamskhou EA, Kratochvil MJ, Orcholski ME, Nagy N, Kaber G, Steen E, Balaji S, Yuan K, Keswani S, Danielson B. Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials. 2019;203:52\u201362.","journal-title":"Biomaterials"},{"issue":"5","key":"1971_CR91","first-page":"1","volume":"2020","author":"AS Ojo","year":"2020","unstructured":"Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. BMC Pulm Med. 2020;2020(5):1\u201310.","journal-title":"BMC Pulm Med"},{"key":"1971_CR92","doi-asserted-by":"publisher","first-page":"e01041","DOI":"10.1016\/j.idcr.2020.e01041","volume":"23","author":"MA Alhiyari","year":"2021","unstructured":"Alhiyari MA, Ata F, Alghizzawi MI, Bilal ABI, Abdulhadi AS, Yousaf Z. Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection. IDCases. 2021;23:e01041.","journal-title":"IDCases"},{"key":"1971_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:1\u201333.","journal-title":"J Nanobiotechnol"},{"key":"1971_CR94","doi-asserted-by":"publisher","first-page":"114173","DOI":"10.1016\/j.addr.2022.114173","volume":"183","author":"V Forest","year":"2022","unstructured":"Forest V, Pourchez J. Nano-delivery to the lung-by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliver Rev. 2022;183:114173.","journal-title":"Adv Drug Deliver Rev"},{"key":"1971_CR95","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ajps.2015.08.009","volume":"10","author":"W-H Lee","year":"2015","unstructured":"Lee W-H, Loo C-Y, Traini D, Young PM. Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges. Asian J Pharm Sci. 2015;10:481\u20139.","journal-title":"Asian J Pharm Sci"},{"key":"1971_CR96","doi-asserted-by":"publisher","first-page":"119969","DOI":"10.1016\/j.lfs.2021.119969","volume":"285","author":"N Gulati","year":"2021","unstructured":"Gulati N, Chellappan DK, MacLoughlin R, Dua K, Dureja H. Inhaled nano-based therapeutics for inflammatory lung diseases: recent advances and future prospects. Life Sci. 2021;285:119969.","journal-title":"Life Sci"},{"key":"1971_CR97","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/adt.2020.998","volume":"18","author":"G H\u00e4drich","year":"2020","unstructured":"H\u00e4drich G, Boschero RA, Appel AS, Falkembach M, Monteiro M, da Silva PEA, Dailey LA, Dora CL. Tuberculosis treatment facilitated by lipid nanocarriers: can inhalation improve the regimen? Assay Drug Dev Technol. 2020;18:298\u2013307.","journal-title":"Assay Drug Dev Technol"},{"key":"1971_CR98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1039\/D1NR06512B","volume":"14","author":"W Tang","year":"2022","unstructured":"Tang W, Zhang Y, Zhu G. Pulmonary delivery of mucosal nanovaccines. Nanoscale. 2022;14:263\u201376.","journal-title":"Nanoscale"},{"key":"1971_CR99","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. First-in-human study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of LQ036 [EB\/OL]. (2023-04-13) [2023-05-19] https:\/\/beta.clinicaltrials.gov\/study\/NCT04993443."},{"key":"1971_CR100","unstructured":"U.S. National Library of Medicine. Clinical Trials.gov. A phase 1 study of VX-522 in participants with cystic fibrosis (CF) [EB\/OL]. (2023-05-01) [2023-05-04] https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05668741."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01971-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T05:03:50Z","timestamp":1688792630000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01971-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01971-7","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have included 10 figures (Figs.\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      ,\n                      \n                      and\n                      \n                      ) from previously published literature with required copyright permission from the copyright owners. We have mentioned this in the manuscript with appropriate citations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}